Skip to the beginning of the images gallery

Dostarlimab (anti-PD-1) - Primary antibody, specific to PDCD1, >95%, high purity, Human IgG4SP, Antibody of programmed cell death 1 (CD279)

≥95%(SDS-PAGE&SEC)
Lot by Lot

Application:

Animal Model
ELISA
Flow Cytometry
Functional Assay

Features and benefits

Host species: Human
Species reactivity(Reacts with): Cynomolgus monkey,Human
Isotype: Human IgG4SP
Conjugation: Unconjugated

Item Number

Ab175513

Grouped product items
SKU	Size	Availability	Price
Ab175513-100μg	100μg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$79.90
Ab175513-1mg	1mg	In stock	$379.90
Ab175513-5mg	5mg	In stock	$989.90
Ab175513-10mg	10mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$1,589.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

View related series

Click to view target information: PDCD1

Accession#:Q15116 Gene ID:5133 PD1 PDCD1 programmed cell death 1 (CD279) Antibody

Basic Description

Product Name	Dostarlimab (anti-PD-1) - Primary antibody, specific to PDCD1, >95%, high purity, Human IgG4SP
Synonyms	CD279 antibody \| CD279 antigen antibody \| hPD 1 antibody \| hPD l antibody \| hPD-1 antibody \| hSLE1 antibody \| PD 1 antibody \| PD-1 antibody \| PD1 antibody \| PDCD 1 antibody \| PDCD1 antibody \| PDCD1_HUMAN antibody \| Programmed cell death 1 antibody \| Progr
Specifications & Purity	ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
Host species	Human
Specificity	PDCD1
Conjugation	Unconjugated
Grade	Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action Type	ANTAGONIST
Mechanism of action	Antibody of programmed cell death 1 (CD279)
Product Description	Dostarlimab (anti-PD-1) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab (anti-PD-1) binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively[1].

Product Properties

Isotype	Human IgG4SP
Light Chain Type	kappa
SDS-PAGE	26.6 kDa (Light Chain) & 50.8 kDa (Heavy Chain), under reducing conditions; 180.0 kDa, under non-reducing conditions.
Purification Method	Protein A purified
Purity	>95%
Form	Liquid
Concentration	Lot by Lot
Storage Temp	Store at -80°C,Avoid repeated freezing and thawing
Shipped In	Ice chest + Ice pads
Stability And Storage	Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS	2022215-59-2

Images

Dostarlimab (anti-PD-1) (Ab175513) - ELISA
Immobilized Human PDCD1/PD-1/CD279-his at 2 μg/mL can bind Dostarlimab (anti-PD-1) (Ab175513) with the EC₅₀ of 12.16 ng/mL.

Dostarlimab (anti-PD-1) (Ab175513) - SEC
The purity of Dostarlimab (anti-PD-1) (Ab175513) is more than 95% verified by HPLC.

Dostarlimab (anti-PD-1) (Ab175513) - ELISA
Immobilized Recombinant Human PD-1 Protein (rp176241) at 1.0 μg/mL can bind Dostarlimab (anti-PD-1) (Ab175513) with the EC50 of 32.41 ng/mL.

Associated Targets(Human)

PDCD1 Tclin Programmed cell death protein 1 (0 Activities)

Discover Target: PDCD1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PDCD1 Tclin Programmed cell death protein 1 (14 Activities)

Discover Target: PDCD1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

2 results found

Lot Number	Certificate Type	Date	Item
ZJ23F1202182	Certificate of Analysis	Dec 22, 2023	Ab175513
ZJ23F1202181	Certificate of Analysis	Dec 22, 2023	Ab175513

References

1. Kline J, Gajewski TF. (2010) Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.. Curr Opin Investig Drugs, 11 (12): (1354-9). [PMID:21154117] [10.1021/op500134e]
2. Hall RD, Gray JE, Chiappori AA. (2013) Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.. Cancer Control, 20 (1): (22-31). [PMID:23302904] [10.1021/op500134e]
3. Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q et al.. (2017) Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.. Mol Cancer Ther, 16 (5): (861-870). [PMID:28265006] [10.1021/op500134e]
4. Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Dömling A, Dubin G, Holak TA. (2015) Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.. Structure, 23 (12): (2341-2348). [PMID:26602187] [10.1021/op500134e]
5. L R Finger,J Pu,R Wasserman,R Vibhakar,E Louie,R R Hardy,P D Burrows,L G Billips. (1997-10-23) The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors.. Gene, 197 ((1-2)): (177-187). [PMID:9332365]
6. Cheng B, Ren Y, Niu X, Wang W, Wang S, Tu Y, Liu S, Wang J, Yang D, Liao G, Chen J.. (2020) Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents.. J Med Chem, 63 (15): (8338-8358). [PMID:32667799] [10.1021/acs.jmedchem.0c00574]
7. Shinohara, T T, Taniwaki, M M, Ishida, Y Y, Kawaichi, M M and Honjo, T T.. (1994) Structure and chromosomal localization of the human PD-1 gene (PDCD1).. Genomics, [PMID:7851902]
8. Prokunina, Ludmila L and 23 more authors.. (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans.. Nature genetics, [PMID:12402038]
9. Topalian, Suzanne L SL and 29 more authors.. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.. The New England journal of medicine, (28): [PMID:22658127]
10. Robert, Caroline C and 27 more authors.. (2015) Nivolumab in previously untreated melanoma without BRAF mutation.. The New England journal of medicine, (22): [PMID:25399552]
11. McDermott, J J and Jimeno, A A.. (2015) Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.. Drugs of today (Barcelona, Spain : 1998), [PMID:25685857]
12. Na, Zhenkun and 6 more authors.. (2017) Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab.. Cell research, [PMID:27325296]
13. Pascolutti, Roberta R and 6 more authors.. (2016) Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant.. Structure (London, England : 1993), (4): [PMID:27618663]
14. Horita, Shoichiro S and 5 more authors.. (2016) High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1.. Scientific reports, (13): [PMID:27734966]
15. Tan, Shuguang S and 15 more authors.. (2017) An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.. Nature communications, (6): [PMID:28165004]
16. Berger, Kristin Nicole KN and Pu, Jeffrey Jiayu JJ.. (2018) PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene.. Gene, (5): [PMID:28951311]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.